目的 探討維肝福泰片聯(lián)合熊去氧膽酸治療原發(fā)性膽汁性肝硬化的臨床療效。方法 回顧性分析2018年2月—2019年2月在安陽市第五人民醫(yī)院治療的102例原發(fā)性膽汁性肝硬化患者的臨床資料，依據(jù)用藥的不同分為對照組和治療組，每組各51例。對照組口服熊去氧膽酸膠囊，每天10 mg/kg；治療組在對照組基礎(chǔ)上口服維肝福泰片，3片/次，3次/d。兩組患者均連續(xù)治療6個月。觀察兩組患者臨床療效，比較治療前后兩組患者肝功相關(guān)指標(biāo)丙氨酸氨基轉(zhuǎn)移酶（ALT）、天門冬氨酸氨基轉(zhuǎn)移酶（AST）、堿性磷酸酶（ALP）、總膽紅素（TBIL）、谷氨酰轉(zhuǎn)肽酶（GGT），黃疸、面色晦暗、肝區(qū)不適、皮膚瘙癢和乏力消失時間及血清白細胞介素-17（IL-17）、血小板衍生生長因子（PDGF）、IL-22、轉(zhuǎn)化生長因子-β（TGF-β）、二胺氧化酶（DAO）、內(nèi)毒素和D-乳酸水平。結(jié)果 經(jīng)治療，對照組總有效率明顯低于治療組（82.35% vs 98.04%，P<0.05）。經(jīng)治療，兩組ALT、AST、ALP、TBiL、GGT水平均顯著下降，且治療組最降低最明顯（P<0.05）。經(jīng)治療，治療組臨床癥狀消失時間均顯著早于對照組（P<0.05）。治療后，兩組患者血清IL-17、PDGF和IL-22水平均顯著降低，而TGF-β水平明顯升高（P<0.05），且治療組明顯好于對照組（P<0.05）。治療后，兩組患者血清DAO、內(nèi)毒素、D-乳酸水平均顯著下降（P<0.05），且治療組下降最明顯（P<0.05）。結(jié)論 維肝福泰片聯(lián)合熊去氧膽酸治療原發(fā)性膽汁性肝硬化療效顯著，不但可顯著改善患者臨床體征和肝功能水平，而且對患者腸黏膜屏障功能的恢復(fù)也有著積極作用。

Objective To investigate the clinical efficacy of Weigan Futai Tablets combined with ursodeoxycholic acid in treatment of primary biliary cirrhosis. Methods The clinical data of 102 patients with primary biliary cirrhosis in the Fifth People's Hospital of Anyang from February 2018 to February 2019 were retrospectively analyzed. These patients were divided into control and treatment groups according to the difference of drugs, and each group had 51 cases. Patients in the control group were po administered with Ursodeoxycholic Acid Capsules, 10 mg/kg daily. Patients in the treatment group po administered with Weigan Futai Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the liver function indexes of ALT, AST, ALP, TBiL and GGT, and the disappearance time of jaundice, dark complexion, liver discomfort, skin itching and fatigue, and the serum levels of IL-17, PDGF, IL-22 and TGF-β in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the control group was significantly lower than that of the treatment group (82.35% vs 98.04%, P<0.05). After treatment, the levels of ALT, AST, ALP, TBiL, and GGT were significantly decreased in two groups (P<0.05), and which in treatment group were more significantly decreased (P<0.05). After treatment, the disappearance time of clinical symptoms in treatment group was significantly earlier than that in control group (P<0.05). After treatment, the serum levels of IL-17, PDGF, and IL-22 in two groups were significantly decreased, while the levels of TGF-β were significantly increased (P<0.05), and the treatment group was significantly better than the control group (P<0.05). After treatment, the levels of serum DAO, endotoxin and D-lactic acid in two groups were significantly decreased (P<0.05), especially in the treatment group (P<0.05). Conclusion Weigan Futai Tablets combined with ursodeoxycholic acid in treatment of primary biliary cirrhosis has a remarkable curative effect, which can not only significantly improve the clinical signs and liver function of patients, but also play a positive role in the recovery of intestinal mucosal barrier function.

R975

北京醫(yī)衛(wèi)健康公益基金項目（YWJKJJHKYJJ-B17715）